Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 473

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 473
---
 | Meningitis, traveland endemicsvaccines |    204 |          736 |            376 |  1,316 |    157 |          730 |            379 |   1,266 |    112 |          767 |            430 |   1,309 |
| Of which total launches |                                        |    960 |        2,998 |            577 |  4,535 |    491 |        1,533 |            213 |   2,237 |    215 |          623 |            113 |     951 |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation .

| F-94 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

D.34.2. Other revenues

| (€ million)                                                    |  2024 | 2023(a) | 2022(a) |
| VaxServe sales of non-Sanofi products                          | 1,959 |   2,167 |   1,567 |
| COVID-19 vaccine related revenues                              |     — |     509 |     257 |
| Intragroup sales from continuing to discontinued operations(b) |   163 |     188 |     208 |
| Royalties                                                      |   121 |     107 |     103 |
| Other(c)                                                       |   623 |     534 |     399 |
| Total Biopharma Other revenues                                 | 2,866 |   3,505 |   2,534 |
| Sales / Revenues from Opella products(d)                       |   339 |     296 |     376 |
| Total Other revenues                                           | 3,205 |   3,801 |   2,910 |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities

within the scope of discontinued operations.

(c) This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties.

(d) Consumer Healthcare activities that will not be transferred